These results show that unselective COX inhibitors are a feasible pharmacologic way to raise the intratumoral levels of CXCR3 ligands in human breast cancer with the objective to increase tumor infiltration by tumor-suppressive immune cells and improve the outcome of breast cancer therapy. Here, CXCR3 is linked to breast cancer.